Recent preclinical candidates for hantavirus vaccines, including DNA-based formulations targeting Andes and Hantaan strains, have shown promising neutralizing antibody responses in early animal models and limited Phase 1 human trials, yet none have advanced beyond initial safety and immunogenicity testing as of mid-2026. Development timelines typically require several additional years for Phase 2 and 3 efficacy studies plus regulatory review, consistent with historical patterns for rare rodent-borne orthohantaviruses lacking urgent pandemic-scale funding. Trader consensus on the 91.5 percent “No” outcome reflects these extended regulatory and manufacturing hurdles, though accelerated federal support or breakthrough trial results could modestly shift probabilities if new data emerge before year-end.